Alteogen Reports Completion of P-I Study of ALT-L9 (biosimilar, aflibercept) in Korea
Shots: The P-III HLX04-mCRC03 study involves assessing the efficacy, safety and immunogenicity of HLX04 vs reference bevacizumab (7.5 mg/kg, q3w or 5 mg/kg, q2w) + CT (Xelox or mFOLFOX6) as a 1L treatment in patients in the ratio of (1:1) with mCRC Result: PFSR36wk (46.4% vs 50.7%); no significant difference b/w the treatment groups in […]Read More